- Home
- DQ vs JANX Comparison
DQ vs JANX Comparison
Compare DQ & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- JANX
- Stock Information
- Founded
- DQ 2006
- JANX 2017
- Country
- DQ China
- JANX United States
- Employees
- DQ N/A
- JANX N/A
- Industry
- DQ Semiconductors
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- JANX Health Care
- Exchange
- DQ Nasdaq
- JANX Nasdaq
- Market Cap
- DQ 1.4B
- JANX 1.6B
- IPO Year
- DQ 2010
- JANX 2021
- Fundamental
- Price
- DQ $13.36
- JANX $23.80
- Analyst Decision
- DQ Hold
- JANX Strong Buy
- Analyst Count
- DQ 6
- JANX 7
- Target Price
- DQ $20.31
- JANX $94.29
- AVG Volume (30 Days)
- DQ 694.1K
- JANX 1.3M
- Earning Date
- DQ 04-29-2025
- JANX 05-08-2025
- Dividend Yield
- DQ N/A
- JANX N/A
- EPS Growth
- DQ N/A
- JANX N/A
- EPS
- DQ N/A
- JANX N/A
- Revenue
- DQ $737,683,000.00
- JANX $9,336,000.00
- Revenue This Year
- DQ N/A
- JANX N/A
- Revenue Next Year
- DQ $90.46
- JANX $283.88
- P/E Ratio
- DQ N/A
- JANX N/A
- Revenue Growth
- DQ N/A
- JANX 28.12
- 52 Week Low
- DQ $12.41
- JANX $22.48
- 52 Week High
- DQ $30.85
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- DQ 41.53
- JANX 39.00
- Support Level
- DQ $13.51
- JANX $23.52
- Resistance Level
- DQ $14.11
- JANX $26.46
- Average True Range (ATR)
- DQ 0.61
- JANX 1.79
- MACD
- DQ 0.04
- JANX -0.00
- Stochastic Oscillator
- DQ 4.56
- JANX 27.53
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.